TY - CONF
T1 - Phase I/II open label nonrandomized safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 immunotherapy in combination with PD-1 checkpoint blockade in intermediate-risk localized or locally advanced prostate cancer and advanced metastatic prostate cancer.
JO - JOURNAL OF CLINICAL ONCOLOGY
PY - 2020/01/01
AU - Tuthill M
AU - Cappuccini F
AU - Bryant RJ
AU - Poulton I
AU - Pollock E
AU - Carter L
AU - Verrill C
AU - Meier A
AU - Schmidt G
AU - Catto JWF
AU - Evans T et al
ED -
VL - 38
IS - 15
Y2 - 2025/01/07
ER -